Log in

Immutep Stock Price, News & Analysis (ASX:IMM)

0.00 (0.00 %)
(As of 10/16/2019 04:10 AM ET)
Today's Range
Now: A$0.03
50-Day Range
MA: A$0.02
52-Week Range
Now: A$0.03
Volume20.47 million shs
Average VolumeN/A
Market Capitalization$95.53 million
P/E RatioN/A
Dividend YieldN/A
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti) with KEYTRUDA therapy, an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer, as well as in a Phase I combination therapy trial in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody, which is in a Phase I clinical trial for use in autoimmune diseases; IMP701, a LAG-3 antagonist antibody that is in a Phase I/II clinical trial, which is used for the treatment of cancer; and IMP761, an agonist of LAG-3 for treating autoimmune diseases. The company has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate the combination of efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies; and partnerships with GlaxoSmithKline, Novartis, and EOC Pharma for the development of LAG-3 product candidates. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Phone61 2 8315 7003



Sales & Book Value

Annual Sales$5.64 million
Cash FlowA$0.00 per share
Book ValueA$0.01 per share



Outstanding Shares3,411,780,096
Market Cap$95.53 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMM News and Ratings via Email

Sign-up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.

Immutep (ASX:IMM) Frequently Asked Questions

What is Immutep's stock symbol?

Immutep trades on the ASX under the ticker symbol "IMM."

Has Immutep been receiving favorable news coverage?

News coverage about IMM stock has been trending very negative on Wednesday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immutep earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Immutep.

Who are some of Immutep's key competitors?

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Geron (GERN), Opko Health (OPK), Micron Technology (MU), Immersion (IMMR), Evoke Pharma (EVOK), DURECT (DRRX), Denali Therapeutics (DNLI), Accuray (ARAY), Starpharma (SPL) and Mesoblast (MSB).

Who are Immutep's key executives?

Immutep's management team includes the folowing people:
  • Mr. Marc Voigt, Exec. Director, CEO, CFO & Chief Bus. Officer (Age 46)
  • Ms. Deanne Miller, COO, Gen. Counsel & Company Sec. (Age 42)
  • Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer (Age 64)
  • Mr. Jay R. Campbell, Chief Bus. Officer and VP of Bus. Devel. & Investor Relations
  • Mr. David Fang, Fin. Director & Assistant Company Sec.

What is Immutep's stock price today?

One share of IMM stock can currently be purchased for approximately A$0.03.

How big of a company is Immutep?

Immutep has a market capitalization of $95.53 million and generates $5.64 million in revenue each year. View Additional Information About Immutep.

What is Immutep's official website?

The official website for Immutep is http://www.primabiomed.com.au/.

How can I contact Immutep?

The company can be reached via phone at 61 2 8315 7003.

MarketBeat Community Rating for Immutep (ASX IMM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  8 (Vote Underperform)
Total Votes:  19
MarketBeat's community ratings are surveys of what our community members think about Immutep and other stocks. Vote "Outperform" if you believe IMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel